Life Science News

IDBS, a Danaher operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management platform. Extracting valuable insights from process and quality data across the biopharmaceutical lifecycle is a time consuming and error prone process, requiring laborious manual work and multiple steps. IDBS Polar replaces paper records, spreadsheets ...

IDBS, a Danaher (NYSE:DHR) operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management (BPLM) platform.

Extracting valuable insights from process and quality data across the biopharmaceutical lifecycle is a time consuming and error prone process, requiring laborious manual work and multiple steps.

IDBS Polar replaces paper records, spreadsheets and ad-hoc software tools with integrated digital workflows, eliminating silos and delivering a high quality data backbone from development through manufacturing.  Polar Insight enables users with advanced data modelling and visualization tools, reducing the reliance on data science experts for common analysis requests such as comparing bioreactor runs or complex data sets over multiple campaigns.

Polar Insight unlocks the value of data and knowledge at all stages of the lifecycle, accelerating innovation, regulatory filings and technology transfer. These new tools will help our customers deliver life changing vaccines and therapies to patients faster and more cost effectively.

The first data analytics dashboards for biopharma development scientists will be available starting in Q1 2022.

"Turning development and manufacturing data into actionable insight is an increasing challenge across the biopharma lifecycle with much of the data locked away in inaccessible silos," said Pietro Forgione , VP Strategy at IDBS. "Polar BPLM is designed to efficiently navigate the complex landscape of processes and data. With these new capabilities, we are helping our customers dramatically reduce their time-to-insight, spending less time on data administration and providing the dashboards they need to design, scale-up and transfer more robust and higher yielding processes."

"By bringing Polar together with our recent acquisition of Skyland Analytics, we can now provide cutting edge insight and analytics capabilities from early development through commercial manufacturing. We are excited to be helping our customers accelerate their time to market with the world's first end-to-end BioPharma Lifecycle Management platform."

More information can be found here. https://www.idbs.com/polar/insight/

About IDBS

IDBS helps research and development (R&D) teams around the world make discoveries that have the potential to transform the lives of populations worldwide. IDBS Polar is the world's first BioPharma Lifecycle Management (BPLM) system, a cloud-based platform designed to accelerate biopharmaceutical development by tackling the biggest challenges in process design, optimisation, scale-up and technology transfer.

Our diverse customer list includes 22 of the top 25 global pharmaceutical companies, and other R&D-driven organizations in biotechnology, agricultural sciences, chemicals, consumer goods, energy, food and beverage, and healthcare serving over 50,000 researchers in 25 countries. For more information visit www.idbs.com .

MEDIA ENQUIRIES

e | mediaenquiries@idbs.com

View original content: https://www.prnewswire.com/news-releases/idbs-polar-insight-brings-advanced-data-analytics-and-visualization-to-biopharma-lifecycle-management-301433269.html

SOURCE IDBS

News Provided by PR Newswire via QuoteMedia

Medtronic announces results showing meaningful pain relief using DTM Spinal Cord Stimulation endurance therapy

DTM™ SCS endurance therapy enables long-lasting recharge-free performance on Vanta™ and 5-minute recharge on Intellis™ neurostimulators

- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced three-month results from an on-label, prospective, multi-center study 1 showing meaningful pain relief using DTM™ SCS endurance therapy, a modified, lower-energy variation of the company's Differential Target Multiplexed™ (DTM) Spinal Cord Stimulation (SCS) therapy for chronic overall, back or leg pain. At 3 months, patients treated with DTM SCS endurance therapy reported meaningful pain relief as measured by a 3.9 cm reduction in overall pain on the 10 cm Visual Analog Scale (VAS) 2 . Patients also reported an average 4.3 cm decrease in back pain, and an average 5.0 cm decrease in leg pain.

Keep reading... Show less

Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering

- Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") announced today that, in connection with its previously announced intention to separate its eye health business, its wholly owned subsidiary, Bausch + Lomb Corporation ("Bausch + Lomb"), has publicly filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") and a preliminary base post-receipt pricing procedure ("PREP") prospectus with the securities regulatory authorities in each of the provinces and territories of Canada (other than Quebec ) ("Canadian Regulators") relating to a proposed initial public offering ("IPO") of Bausch + Lomb's common shares concurrently in the United States and Canada . All of the shares being offered will be sold by a wholly owned subsidiary of Bausch Health. The number of common shares to be offered and the price range for the IPO have not yet been determined.

Morgan Stanley and Goldman Sachs & Co. LLC are acting as joint lead book-running managers for the IPO. J.P. Morgan, Citigroup, Barclays, BofA Securities, Guggenheim Securities, Jefferies, Evercore ISI, Wells Fargo Securities and Deustche Bank Securities are acting as joint book-running managers for the IPO, and DNB Markets, HSBC and Truist Securities are acting as co-managers for the IPO.

Keep reading... Show less

Medtronic announces schedule for presentations at the 2022 North American Neuromodulation Society Meeting

Sessions will include DTM™ SCS endurance therapy 3-month outcomes for patients with chronic back and leg pain

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced its schedule for presentations at the 25th Annual North American Neuromodulation Society meeting, taking place January 13-15, 2022 in Orlando, Florida . Medtronic therapies and technologies will be represented as part of 23 podium and poster presentations. The company will also welcome guests to booth #404 featuring an innovation suite and opportunities to learn from Medtronic scientists and engineers about the new Vanta™ recharge-free neurostimulator, as well as a new modified energy variation of Differential Target Multiplexed™ (DTM) Spinal Cord Stimulation known as DTM™ SCS endurance therapy. Medtronic will also showcase its targeted drug delivery options for patients with chronic pain.

Keep reading... Show less

Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms

- Abbott (NYSE: ABT) today announced it has received clearance from the U.S. Food and Drug Administration for the EnSite™ X EP System with EnSite Omnipolar Technology (OT), a new cardiac mapping platform available in the U.S. and across Europe that is designed to help physicians better treat abnormal heart rhythms, also known as cardiac arrhythmias. Designed with input from electrophysiologists from around the world, the system creates highly detailed three-dimensional maps of the heart to help physicians identify and then treat areas of the heart where abnormal rhythms originate.

"More patients than ever before are benefitting from ablation to treat abnormal heart rhythms, and Abbott's new EnSite X System with EnSite OT, utilizing Advisor HD Grid catheter, embodies the latest innovation available to support the treatment of complex and challenging cardiac arrhythmias," said Amin Al-Ahmad , M.D., a clinical cardiac electrophysiologist with Texas Cardiac Arrhythmia at St. David's Medical Center in Austin, Texas . "To continue improving outcomes for our patients, we need a system with speed, stability and accuracy. Abbott has provided us with a system that not only supports safe and effective treatment, but enhances the accuracy of maps, allowing for a clearer understanding of what is going on in the heart and what areas need to be targeted with ablation to treat arrythmias."

Keep reading... Show less

Pall Corporation's new Supralon Filter Element Advances Equipment Protection and Reduces Energy Costs

- Pall Corporation, a leader in filtration, separation and purification technology and a Danaher operating company, launched the new Supralon TM hydraulic and lube oil filter element range, a direct upgrade for Pall's Coralon ® Ultipor ® and Red1000 series filters. Supralon filter elements incorporate a new pack construction with filter media utilizing stress-resistant technology (SRT) and showcasing anti-static properties, which ultimately help protect and prolong the life of equipment in hydraulic and lube oil applications.

Keep reading... Show less

ACELYRIN Appoints Melanie Gloria as Chief Operating Officer

- ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie Gloria BSN, as the company's chief operating officer (COO). In this role, Ms. Gloria will oversee business operations across the company.

Keep reading... Show less

Latest Press Releases

Related News

×